OBJECTIVES: The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by 18F-Fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI. BACKGROUND: PSO, a chronic inflammatory skin disease, is associated with VI by 18F-FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation. Recently, VI was associated with future cardiovascular events; however, the relationship of visceral and subcutaneous adiposity with VI in PSO has yet to be evaluated. METHODS: Consecutive PSO patients (N = 77) underwent 18F-FDG PET/CT scans to measure VI and abdominal adiposity. A subset of PSO patients with severe skin disease was scanned at 1 year following PSO treatment (N = 13). RESULTS: The cohort was middle aged (51.8 ± 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (β = 0.33; p = 0.004) beyond SAT (β = 0.30; p = 0.005). VAT (β = 0.55; p < 0.001), but not SAT (β = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (β = 0.53; p = 0.049). CONCLUSIONS: Volume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO. Published by Elsevier Inc.
OBJECTIVES: The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by 18F-Fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI. BACKGROUND: PSO, a chronic inflammatory skin disease, is associated with VI by 18F-FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation. Recently, VI was associated with future cardiovascular events; however, the relationship of visceral and subcutaneous adiposity with VI in PSO has yet to be evaluated. METHODS: Consecutive PSO patients (N = 77) underwent 18F-FDG PET/CT scans to measure VI and abdominal adiposity. A subset of PSO patients with severe skin disease was scanned at 1 year following PSO treatment (N = 13). RESULTS: The cohort was middle aged (51.8 ± 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (β = 0.33; p = 0.004) beyond SAT (β = 0.30; p = 0.005). VAT (β = 0.55; p < 0.001), but not SAT (β = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (β = 0.53; p = 0.049). CONCLUSIONS: Volume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO. Published by Elsevier Inc.
Authors: Amit K Dey; Aditya A Joshi; Abhishek Chaturvedi; Joseph B Lerman; Tsion M Aberra; Justin A Rodante; Heather L Teague; Charlotte L Harrington; Joshua P Rivers; Jonathan H Chung; Mohammad Tarek Kabbany; Balaji Natarajan; Joanna I Silverman; Qimin Ng; Gregory E Sanda; Alexander V Sorokin; Yvonne Baumer; Emily Gerson; Ronald B Prussick; Alison Ehrlich; Lawrence J Green; Benjamin N Lockshin; Mark A Ahlman; Martin P Playford; Joel M Gelfand; Nehal N Mehta Journal: JAMA Cardiol Date: 2017-09-01 Impact factor: 14.676
Authors: R C Li; P Krishnamoorthy; S DerOhannessian; J Doveikis; M Wilcox; P Thomas; D J Rader; M P Reilly; A Van Voorhees; J M Gelfand; N N Mehta Journal: Clin Exp Dermatol Date: 2014-01 Impact factor: 3.470
Authors: Taufiq Salahuddin; Balaji Natarajan; Martin P Playford; Aditya A Joshi; Heather Teague; Youssef Masmoudi; Mariana Selwaness; Marcus Y Chen; David A Bluemke; Nehal N Mehta Journal: Eur Heart J Date: 2015-07-18 Impact factor: 29.983
Authors: Martin P Playford; Amit K Dey; Claudia Zierold; Aditya A Joshi; Frank Blocki; Fabrizio Bonelli; Justin A Rodante; Charlotte L Harrington; Joshua P Rivers; Youssef A Elnabawi; Marcus Y Chen; Mark A Ahlman; Heather L Teague; Nehal N Mehta Journal: Atherosclerosis Date: 2019-08-17 Impact factor: 5.162
Authors: Joel M Gelfand; Daniel B Shin; April W Armstrong; Stephen K Tyring; Andrew Blauvelt; Scott Gottlieb; Benjamin N Lockshin; Robert E Kalb; Robert Fitzsimmons; Justin Rodante; Philip Parel; Grigory A Manyak; Laurel Mendelsohn; Megan H Noe; Maryte Papadopoulos; Maha N Syed; Thomas J Werner; Joy Wan; Martin P Playford; Abass Alavi; Nehal N Mehta Journal: JAMA Dermatol Date: 2022-09-21 Impact factor: 11.816
Authors: Milena Aksentijevich; Sundus S Lateef; Paula Anzenberg; Amit K Dey; Nehal N Mehta Journal: Trends Cardiovasc Med Date: 2019-11-20 Impact factor: 6.677
Authors: Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao Journal: J Invest Dermatol Date: 2021-04-19 Impact factor: 7.590
Authors: Aparna Sajja; Khaled M Abdelrahman; Aarthi S Reddy; Amit K Dey; Domingo E Uceda; Sundus S Lateef; Alexander V Sorokin; Heather L Teague; Jonathan Chung; Joshua Rivers; Aditya A Joshi; Youssef A Elnabawi; Aditya Goyal; Justin A Rodante; Andrew Keel; Julie E Alvarez; Benjamin Lockshin; Ronald Prussick; Evan Siegel; Martin P Playford; Marcus Y Chen; David A Bluemke; Joel M Gelfand; Nehal N Mehta Journal: JCI Insight Date: 2020-11-19
Authors: Andrej Ćorović; Christopher Wall; Justin C Mason; James H F Rudd; Jason M Tarkin Journal: Curr Cardiol Rep Date: 2020-08-09 Impact factor: 3.955